Tofersen, now known as Qalsody, targets a specific genetic mutation, SOD1, present in 2% of patients with amyotrophic lateral sclerosis (ALS). This drug has been shown to slow and even reverse the progression of symptoms in selected patients.
A recent randomized, controlled clinical trial has shown significant stabilization of symptoms in participants who received tofersen.
More than 20% of these patients experienced improvements in muscle strength and function over three years, a notably unusual outcome in the context of ALS treatment.
Dr. Timothy Miller, David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis and lead author of the study, told ABC News about the significance of these findings, suggesting this could be a crucial step toward effective treatments that target the underlying genetic causes of ALS.
“This is the first study in which we’ve seen a really dramatic stabilization and slowing. I think, because of this study, we know that some forms of ALS are treatable,” he said.
ALS is a disorder A neurological disease that affects nerve cells in the brain and spinal cord, controlling voluntary muscle movement and breathing.
Patient Testimonials
Jessica Morris, a patient who began using tofersen through expanded access, has reported significant improvements in her quality of life. After experiencing muscle weakness and wheelchair dependence, the medication has allowed her to regain some mobility and perform everyday tasks.
“This drug gives me hope, the hope of a future I never dreamed of having,” Morris told ABC News.
“It’s like winning the lottery to have ALS and have this opportunity to have a drug that is not only supposed to slow the progression, but in my case, helped me get out of the wheelchair.
“That’s very important,” he explained.
A hopeful future
As the number of ALS cases continues to rise, the results of the clinical trial and the stories of patients like Morris offer a ray of hope.
Experts believe this drug could be a game-changer in ALS treatment and improve the quality of life for many, although its benefit is limited to a small percentage of patients.
